

## MEMO

**Date:** April 29, 2025

**To:** ERS Staff

**From:** Tony Herd, Medical Director, Provincial Emergency Response Services  
Shannon Moore, Director, Clinical Standards & Operational Support

**cc:** ERS Leadership  
Dr. Rob Grierson  
Dr. John Sokal

**Re:** **ACP Scope of Work – Medications/Pumps**

---

Effective April 30, 2025, Emergency Response Services (ERS) will implement the Advanced Care Paramedic (ACP) scope of work for Clinical Service Leaders (CSLs) and Education Officers registered at the ACP scope of practice with the College of Paramedics of Manitoba.

As outlined in the ACP Care Maps, this scope of work includes the introduction of several new medications, many of which require administration and titration via mechanical infusion pump.

Unfortunately, due to circumstances beyond our control, mechanical pumps will not be available by the implementation date. Until pumps are in service, ACPs may administer the following medication by infusion only if a mechanical pump is available – regardless of any physician order, including those from a VECTRS physician:

- Epinephrine
- Norepinephrine
- Phenylephrine
- Lidocaine
- Nitroglycerin
- Labetalol
- Esmolol
- Diltiazem
- Dextrose (for newborn hypoglycemia)
- Insulin (for calcium channel blocker or beta blocker toxicity)

Until mechanical pumps are available, only the following medications may be administered via gravity IV drip, with careful monitoring of the drop rate:

- Amiodarone, in the following clinical situations:
  - Return of spontaneous circulation (ROCS) following cardiac arrest
  - Post-electrical cardioversion of unstable tachycardia
  - Chemical cardioversion of stable tachycardia when access to medical care is significantly delayed
- Phenytoin, in cases of status epilepticus, when:
  - Midazolam and levetiracetam have failed to terminate seizures
  - Midazolam has failed, and levetiracetam is contraindicated.

If you have any questions, or require further clarification, please contact the Clinical Manager for your zone.

Thank you for your attention and continued dedication.